USPTO serial 97819704
PRECIGEN
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Feb 20, 2024
- Examiner
- ALESKOW, DAVID HOWARD
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with PRECIGEN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Germantown, MD
Germantown, MD
Germantown, MD
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Sarah P. Harrell
SARAH P. HARRELL BARNES & THORNBURG LLP11 SOUTH MERIDIAN STREETINDIANAPOLIS, IN 46204UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals, biochemicals and reagents for use in industry and science; chemicals, biochemicals and reagents, namely, proteins for regulating, modifying or restricting gene expression; kits consisting primarily of proteins for regulating, modifying or restricting gene expression | ACTIVE | Jan 6, 2020 |
| 005 | Chemical preparations for medical and veterinary purposes, namely, for gene and cell therapy for treating genetic disorders, cancers, rare diseases, infectious diseases, and immunological diseases and disorders; biochemical preparations for medical and veterinary purposes, namely, for gene and cell therapy for treating genetic disorders, cancers, rare diseases, infectious diseases, and immunological diseases and disorders; chemical reagents for medical and veterinary purposes, namely, for gene and cell therapy for treating genetic disorders, cancers, rare diseases, infectious diseases, and immunological diseases and disorders | ACTIVE | Jan 6, 2020 |
| 042 | Scientific research and development services in the field of medicine, pharmacology, immunology, biochemistry, cell biology, genetics, microbiology and virology; Scientific research in the field of healthcare; Therapeutic research of treatments in the fields of oncology, rare diseases, metabolic disorders, and infectious diseases which are under development or have completed development; Development of products being genetic therapies, biopharmaceuticals, and effectors to regulate, modulate, and characterize disease states; Development of tools in the nature of software and biotechnological processes to regulate, modulate, and characterize disease states; Research and development services for others in the field of biotechnology, namely, genetically engineering DNA, biological organisms, cells, viruses, pathogens, and special purpose cells for scientific, research, medical and laboratory use; Research and development services for others in the fields of genetics and biotechnology, namely, genetically engineering DNA, biological organisms, cells, viruses, pathogens, and special purpose cells for scientific, research, medical and laboratory use | ACTIVE | Jan 6, 2020 |
| 044 | Medical services; Medical services, namely, genetic engineering, biopharmaceuticals and gene therapy services; Healthcare services, namely, treatment of patients with genetic disorders, cancers, rare diseases, infectious diseases, and immunological diseases and disorders; Medical services, namely, providing medical therapy treatments which are under development or have completed development for patients in the fields of oncology, rare diseases, metabolic disorders, and infectious diseases | ACTIVE | Jan 6, 2020 |
| 045 | Technology transfer services, namely, licensing of intellectual property | ACTIVE | Jan 6, 2020 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Precigen, Inc.
- Other trademarks owned by Precigen, Inc.
- Other trademarks owned by Precigen, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Other trademarks in Class 045
- Similar marks named PRECIGEN
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 24, 2025 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Feb 20, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Feb 20, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 5, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 5, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 15, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 30, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 30, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 23, 2023 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Mar 22, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 6, 2023 | NWAP | NEW APPLICATION ENTERED | — |